Sign in Subscribe
Food supply

FDA's 100-Day Progress: A New Era of Science, Transparency, and Consumer Protection

Strategic Insights

— 2 min read

The Food and Drug Administration (FDA) has made significant strides in its first 100 days under new leadership, marking a notable shift towards a more transparent, science-driven approach. With a focus on addressing long-standing issues and championing consumer protection, the agency has initiated dozens of key initiatives across its purview.

Key Takeaways:

  • The FDA has launched a comprehensive review of chemicals currently in the food supply, such as BHT, BHA, and ADA, with a focus on prioritizing transparency and public health.
  • The agency has taken bold action to phase out petroleum-based synthetic food dyes from the US food supply, linked to numerous health risks, and approved uses of three food colors derived from natural sources.
  • The FDA has published a roadmap to transition away from animal testing for investigational new drug applications, aiming to reduce the use of animal testing and instead employ more effective, human-relevant methods.
  • The agency has announced the intention to launch a pilot program to expedite drug review processes from 10-12 months to 1-2 months for applications addressing national priorities.
  • The FDA has limited the circumstances under which individuals employed at FDA-regulated companies can serve as members of FDA advisory committees, aimed at mitigating perceived conflicts of interest and strengthening the integrity of the review process.
  • The agency has completed a successful AI-assisted scientific review pilot, demonstrating the potential to greatly reduce time spent on mundane tasks and non-productive busywork.
  • The FDA has initiated a comprehensive effort to consolidate disparate adverse event reporting databases, enabling more effective post-market monitoring of drug products.

Statistics:

  • The FDA regulates products that account for 20% of all US consumer spending, impacting the lives of every American.
  • The agency has launched dozens of key initiatives across its purview, with a focus on addressing big, clear problems in food safety, animal testing, and child health.
  • It took the FDA 100 days to phase out petroleum-based synthetic food dyes from the US food supply.
  • The agency has removed restrictions on certain gene therapies, including BCMA- and CD19-directed autologous chimeric antigen receptor CAR T cell immunotherapies.
  • The FDA has cleared the first in vitro diagnostic device testing blood to aid in diagnosing Alzheimer's disease.
  • Nearly $34 million worth of illegal, youth-appealing e-cigarette products originating in China were seized by the FDA in collaboration with U.S. Customs and Border Protection.

Sources:

  • FDA Press Release: Statement From: "FDA's 100th Day Accomplishments"
  • FDA Press Release: "FDA Marks 100th Day: Progress on Key Initiatives and Commitment to Transparency and Science"
  • FDA Website: "About the FDA"
  • FDA Website: "New Drug Approvals"
  • FDA Website: "Transparency and Accountability"

Read more